Huntington's disease (HD) is an inherited neurodegenerative disorder characterized by dyskinesia, cognitive impairment and emotional disturbances, presenting progressive neurodegeneration in the striatum and intracellular mutant Huntingtin (mHTT) aggregates in various areas of the brain. Recombinant Adeno Associated Viral (rAAV) vectors have been successfully used to transfer foreign genes to the brain of adult animals. In the present study we report a novel in vivo rat HD model obtained by stereotaxic injection of rAAV serotype2/9 containing Exon1-Q138 mHTT (Q138) and Exon1-Q17 wild type HTT (Q17; control), respectively in the right and in the left striatum, and expressed as C-terminal GFP fusions to facilitate detection of infected cells and aggregate production. Immunohistochemical analysis of brain slices from animals sacrificed twenty-one days after viral infection showed that Q138 injection resulted in robust formation of GFP-positive aggregates in the striatum, increased GFAP and microglial activation and neurodegeneration, with little evidence of any of these events in contralateral tissue infected with wild type (Q17) expressing construct. Differences in the relative metabolite concentrations (N-Acetyl Aspartate/Creatine and Myo-Inositol/Creatine) were observed by H1 MR Spectroscopy. By quantitative RT-PCR we also demonstrated that mHTT induced changes in the expression of genes previously shown to be altered in other rodent HD models. Importantly, administration of reference compounds previously shown to ameliorate the aggregation and neurodegeneration phenotypes in preclinical HD models was demonstrated to revert the mutant HTT-dependent effects in our model. In conclusion, the AAV2/9-Q138/Q17 exon 1 HTT stereotaxic injection represents a useful first-line in vivo preclinical model for studying the biology of mutant HTT exon 1 in the striatum and to provide early evidence of efficacy of therapeutic approaches.
Introduction
Huntington's disease (HD) is an inherited neurodegenerative disorder characterized by dyskinesia, cognitive impairment, emotional disturbances and metabolic disorders, predominantly associated with progressive neurodegeneration of medium-spiny neurons in the striatum and with the presence of intracellular Huntingtin (HTT) aggregates in various areas of the brain.
The mutation responsible for HD has been identified as a CAG expansion within the Exon 1 of HTT gene (IT15, located on chromosome 4p16.3), which is translated into a polyQ stretch at the protein level (The Huntington's Disease Collaborative Research Group's, 1993; reviewed by Ross and Tabrizi, 2011; Ha and Fung, 2012; Bates et al., 2015) . Individuals with 35 CAG repeats or fewer do not develop HD, while repeats of 40 and above are invariably associated with disease appearance (Myers et al., 1988) .
Currently there is no effective treatment for preventing or delaying the disease, which typically sets in at around 35-45 years of age and progresses toward death within 10-20 years after the appearance of Abbreviations: HD, Huntington's disease; mHTT, mutant Huntingtin; rAAV, recombinant Adeno Associated Virus; LV, lentivirus; tNAA, total N-Acetyl Aspartate; Myo-Ins, myoinositol; GFP, green fluorescent protein; NeuN, neuronal nuclei; DARPP-32, dopamine-and cyclic AMP-regulated phosphoprotein; ChAT, choline acetyl transferase; GFAP, glial fibrillary acidic protein; Iba-1, ionized calcium binding adaptor molecule 1; PBST, phosphate buffered saline-Triton-X100; BSA, bovine serum albumin; DAB, diaminobenzidine; ROI, region of interest.
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